News | Stents | May 28, 2020

Coronary and Peripheral Stent Market Expected to Double Through 2025

Preference for coronary stents to remain high according to new market analysis

Coronary and Peripheral Stent Market Expected to Double Through 2025

May 28, 2020 — The rising incidence of cardiovascular disease has prompted people to seek timely treatment to improve life expectancies. In the wake of this, the patient demand for minimally invasive, catheter-based stent procedures has accelerated because many want to avoid more invasive open heart coronary artery bypass graft (CABG) surgery. 

A new stent market report from the healthcare market research firm Fact.MR indicates the arterial stent market is poised to expand at a fast compounded annual growth rate (CAGR) of 9.8% during the forecast period of 2020-2025.

 

Key Trends in the Arterial Stent Market:

   • Coronary Stents will dominate the arterial stents market. This is because of an increasing number of coronary artery disease patients and affordability of coronary stents. Anticipated market share is three-fifths of the overall market, growing almost twofold during the forecast period.   

   • Simultaneously, the peripheral femoral and popliteal artery segment is set to experience robust growth of about 10.2% CAGR.

   • Europe is anticipated to dominate the arterial stents market owing to strategic presence of key market players in the interventional cardiology market. This segment is expected to see 9.6% CAGR.

   • Asia-Pacific is not very far behind, with a CAGR of 10.3%. Market penetration by important players and affordability of stents is projected to drive the growth of the region. Coronary Stents are anticipated to hold more than three-fifths of the arterial stents market.

Impact of COVID-19 on the Stent Market

Downsizing of production of arterial stents is anticipated, owing to the spread of the COVID-19 pandemic. Rising infection rates have shifted priority towards addressing patients with COVID-19. This has relegated non-emergency procedures to the backyard, creating a backlog of cardiac patients. However, cardiac complications arising due to the COVID-19 infection such as arrhythmia and tachycardia will be given top priority.

Important players such as Boston Scientific have been contributing significantly to mitigate the spread of the disease. The company has taken significant steps to reduce costs by optimizing manufacturing and output prices and reduction in discretionary spending. It has also undertaken monetary and supply donations along with provision of manufacturing expertise and resources.

“The arterial stents market is projected to embark on a positive growth trajectory, driven primarily by increased demand for minimally invasive surgical procedures. To that end, manufacturers are concentrating heavily on product development and expansion of their portfolio,” concludes a report analyst.

Market Players Resort to Product Distribution to Expand Market Share

Highly fragmented, the arterial stents market has more than 50 players. Out of these, three key players — Medtronic, Abbott and Boston Scientific Corp. — account for three-tenth of the total market share.

Boston Scientific is the leading player. Its product categories include coronary intervention and peripheral intervention. It specializes in drug-eluting stents such as Epic, Express and Innova, Self-expanding stents such as Synergy, Eluvia and Flexive and bare metal stents like Rebel and Promus.

Abbott Vascular offers a broad range of endovascular devices and cardiovascular stents. The products it manufactures include drug-eluting Xience Alpine and bare metal stent Xience Xpedition, the self-expanding Absolute Pro and Omnilink, and balloon-expanding RX Acculink stent.

Related Content

Image from the announcement of the Neal award winner of best technical content for DAIC's coverage of COVID-10 related to cardiology at the Neal virtual award ceremony June 9.

Image from the announcement of the Neal award winner of best technical content for DAIC's coverage of COVID-10 related to cardiology at the Neal virtual award ceremony June 9.

Feature | Cardiovascular Business | June 10, 2021
Avoiding high-risk PCI procedures does not improve hospital scores according to a study presented at SCAI 2021. CTO procedure at Henry Ford Hospital, Detroit. Photo by Dave Fornell.

Avoiding high-risk PCI procedures does not improve hospital scores according to a study presented at SCAI 2021. CTO procedure at Henry Ford Hospital, Detroit. Photo by Dave Fornell.

News | Cardiovascular Business | May 05, 2021
May 5, 2021 — A late-breaking study presented at the...
Cardinal Health Sells its Cordis Cardiology Business to Hellman & Friedman. Hopes to build the Cordis Accelerator for innovative cardiovascular device development.
News | Cardiovascular Business | March 12, 2021
March 12, 2021 — Cardinal Health today announced that it is selling its...
An interventional radiologist consults with a patient in an out patient cath lab at a Modern Vascular clinic. The company is building several out patient clinics to capture a share of the interventional market for peripheral artery disease (PAD) catheter-based therapies. 

An interventional radiologist consults with a patient in an out patient cath lab at a Modern Vascular clinic. The company is building several out patient clinics to capture a share of the interventional market for peripheral artery disease (PAD) catheter-based therapies. 

News | Cardiovascular Business | February 03, 2021
February 3, 2021 — Modern Vascular is a medical group that has 13 outpatient cath lab clinics to treat...
COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States. #DAIC

COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States.

Feature | Cardiovascular Business | December 01, 2020 | Dave Fornell, Editor
December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC
Survey data showing opinions of physicians and hospital administrators on barriers to implementing new technology and how new technologies have improved cardiovascular care.

Survey data showing opinions of physicians and hospital administrators on barriers to implementing new technology and how new technologies have improved cardiovascular care.

News | Cardiovascular Business | September 14, 2020
September 14, 2020 — New global research released by Abbott takes a deep dive into the barriers of cardiovascular pat
Philips angiography system in a cath lab at Henry Ford Hospital.
Feature | Cardiovascular Business | July 13, 2020 | Deb Thompson and Christian Comeau
For a cardiovascular service line leader, addressing challenges in an evolving healthcare climate is a constant.
Leeds Hospital recently installed Philips Azurion angiography interventional labs to enhance procedural guidance capabilities.

Leeds Hospital recently installed Philips Azurion angiography interventional labs to enhance procedural guidance capabilities.

News | Cardiovascular Business | July 08, 2020
July 8, 2020 – Philips Healthcare and Leeds Teaching Hospitals NHS Trust announced a seven-year managed service agree